GSK cancer drug shows early promise in trials

Published: 12 April 2026. The English Chronicle Desk. The English Chronicle Online.

British pharmaceutical giant GSK has reported encouraging early results from a new cancer treatment. The drug targets ovarian and womb cancers, offering hope to patients with limited options. The findings come as the company accelerates its push into oncology development under new leadership.

The treatment, known as Mocertatug Rezetecan or Mo-Rez, has shown notable effectiveness in early trials. According to the company, tumours shrank or disappeared in 62 percent of ovarian cancer patients. These patients had previously failed to respond to chemotherapy. In endometrial cancer cases, the response rate reached 67 percent, marking a significant breakthrough.

The early-stage trial involved 224 patients across several countries, including the United Kingdom. Researchers monitored both effectiveness and safety throughout the study period. Most patients tolerated the treatment well, with nausea reported as the most common side effect. Importantly, only a small number of participants discontinued treatment due to complications.

These findings were presented at the annual meeting of the Society of Gynecologic Oncology in Puerto Rico. The conference is a key platform for advancing women’s cancer research. Experts from around the world gathered to discuss innovations and emerging therapies.

Hesham Abdullah, GSK’s global head of cancer research, highlighted the urgency of new treatments. He noted that gynaecological cancers remain difficult to treat effectively. Current therapies often fail, leaving patients with limited alternatives. He described the Mo-Rez data as compelling and clinically promising.

The drug belongs to a class known as antibody-drug conjugates, often referred to as ADCs. These treatments combine targeted antibodies with powerful chemotherapy agents. The aim is to deliver drugs directly to cancer cells while limiting damage to healthy tissue. This approach has gained increasing attention in recent years.

GSK acquired Mo-Rez from China’s Hansoh Pharma in late 2023. Since then, the company has moved quickly to test its potential globally. The results, combined with additional data from trials in China, have strengthened confidence in the treatment.

Based on these outcomes, GSK plans to move directly into late-stage trials. The company intends to launch five major clinical studies in the coming months. These trials will include patients in the UK, expanding the drug’s evaluation across diverse populations.

Ovarian and endometrial cancers remain major global health concerns. Endometrial cancer affects around 1.6 million women worldwide. Each year, approximately 417,000 new cases are diagnosed. Ovarian cancer impacts more than 843,000 individuals, with 240,000 new cases annually.

Despite medical advances, survival rates for these cancers remain relatively low. Late diagnosis and resistance to treatment often complicate outcomes. This makes the development of new therapies particularly urgent. Mo-Rez could potentially fill a significant gap in current treatment options.

GSK’s renewed focus on oncology reflects a broader strategic shift. The company had previously stepped back from cancer research. In 2015, it sold its oncology portfolio to Novartis. That deal allowed GSK to strengthen its vaccines business at the time.

However, the company has since re-entered the oncology field with renewed ambition. Under former chief executive Emma Walmsley, GSK began rebuilding its cancer pipeline. Today, it has four approved cancer medicines and thirteen in clinical development.

The company’s oncology division has grown rapidly in recent years. Sales in this segment reached nearly £2 billion last year. This marked a 43 percent increase compared to 2024. One of its key products, the endometrial cancer drug Jemperli, saw sales rise by 89 percent.

Now, under the leadership of Luke Miels, GSK aims to accelerate innovation further. Miels, who took over in January, has emphasised what he calls “scientific courage.” He has already announced several strategic deals since assuming the role.

Miels brings extensive experience from his previous roles at AstraZeneca, Roche, and Sanofi-Aventis. His leadership style focuses on speed, agility, and innovation in drug development. Colleagues describe a renewed sense of urgency across the organisation.

Abdullah, who worked with Miels at AstraZeneca, praised this approach. He said the company is embracing faster decision-making and bold scientific thinking. This shift is already visible in the pace of ongoing research programmes.

The competitive landscape in pharmaceuticals remains intense. AstraZeneca has recently outperformed GSK in commercial terms. Last year, its revenue exceeded GSK’s by more than £10 billion. It also gained global recognition for its Covid-19 vaccine developed with Oxford University.

Despite this, GSK continues to build strengths in key areas. The company has received praise for its work on antimicrobial resistance. It remains one of only three major pharmaceutical firms investing in this field. This commitment highlights its broader focus on global health challenges.

Mo-Rez is expected to become a major asset within GSK’s pipeline. Analysts believe it could achieve annual sales exceeding £2 billion. This would make it a blockbuster drug, supporting GSK’s long-term growth targets. The company aims to reach £40 billion in annual sales by 2031.

Experts caution that early-stage results must be confirmed in larger trials. However, the current data has generated cautious optimism. If successful, Mo-Rez could transform treatment options for thousands of patients worldwide.

For patients facing limited choices, these developments bring renewed hope. Advances in targeted therapies continue to reshape cancer care. While challenges remain, progress like this signals a promising future.

As GSK prepares for the next phase of trials, attention will remain focused on outcomes. The coming months will be critical in determining the drug’s long-term potential. For now, the early results represent an important step forward in cancer research.

Related News:

UK Launches World-First Gonorrhoea Vaccine Amid Record Infection Surge AI Tools Used by English Councils Found to Downplay Women’s Health Issues, Raising Concerns Over Gender Bias in Care Breakthrough Clinical Trial Lets 12-Year-Old Boy with Rare Skin Disorder Play Football Hot Tea and Coffee Found to Contain Highest Levels of Microplastics in Popular Drinks Expanded Access to Health Diagnostics in England Now Available Beyond Standard Hours Shocking Rise in Children’s Exposure to Violent Online Pornography Raises Alarm Ed Davey Urges UK to Attract US Cancer Scientists Amid Funding Cuts Under Trump Omeprazole Alert: NHS Issues Guidance on Safe Use for Heartburn and Indigestion GPs in England Warn of Overload as Nationwide Online Appointment System Approaches Eligibility Confusion Over COVID Vaccination Leaves Pharmacies Struggling Across the UK Majority of UK Men Would Opt for Prostate Cancer Screening, Survey Finds Scientists Announce First Potentially Accurate Blood Test for Chronic Fatigue Syndrome NHS May Pay 25% More for Medicines Amid US Drug Talks Survey Shows Most GPs Rushing Appointments Genetic Tests May Predict Return of Blood Cancer UK Woman Becomes Longest Survivor of Heart-Lung Transplant Thousands in the UK sue Johnson & Johnson over alleged talcum powder, linked to cancer ‘Game-Changing’ HIV Prevention Jab Set for NHS Approval Breath test could ‘revolutionise’ pancreatic cancer treatment How Bringing Forests Into Preschools Boosts Children’s Health Experts Urge Legal Right to Timely Cancer Care Patients to Test Health at Home to Ease NHS Winter Pressure North Sea oil workers must lose weight or face job loss No link found between paracetamol in pregnancy and autism UK launches major AI drive to fight deadly superbugs Coffins Now Too Large to Cremate Amid Rising Obesity Crisis Thinktank Urges Smaller Hospitals to End NHS ‘Permacrisis’ NHS paediatric leave parents waiting months for answers Robo-Vaccination Could Transform Fight Against Bovine TB Boy First in UK to Have Surgery to Make Him Taller Mind Launches Inquiry into AI and Mental Health After Guardian Investigation First British baby born using transplanted womb from dead donor Water Cremation Introduced in UK First Streeting Criticises SNP Over NHS App Dispute Surgeon’s op on patient 1,500 miles away a UK first Cancer Death Rate in Britain Falls by Nearly a Third UK Biobank Health Data Leaks Raise Privacy Concerns Meningitis Cases in Kent Outbreak Rise to 27 ‘A Living Nightmare’: Parents of Vaccinated Teenager Speak Out After Rare Meningitis B Battle NHS Enlists AI in Major Push to Slash Hospital Waiting Lists ‘Zoom Dysmorphia’ Explosion: BDD Patients Quadruple in Post-Pandemic UK ‘The Best Decision I Ever Made’: A Mother’s Viral Plea After a Near-Miss with Lung Disease Paws for Peace: Frankie the Cockapoo Brings ‘Unfiltered’ Joy to MND Centre The Friendship Friction: Would You Call Out Your Friend’s Toxic Behaviour? Southern Skies: High Turnout and Surprise Visitors in Birdwatch 2026 The ‘Pain-Free’ Revolution: Hospital Celebrates ‘Seismic’ Hip Surgery Milestone Concerns Mount Over Accuracy of At-Home Health Tests as Study Calls for Stricter Regulation The Ketamine Crisis in the UK is a Silent Epidemic Leaving Users with Lifelong Pain British Pilot Joins Crew Training for Year-Long Mars Simulation Mission Jaguar Land Rover Extends Production Halt Following Cyber-Attack Systemic Racism in Maternity Care Continues to Endanger Black Women in England, MPs Warn One in Three GPs in England Do Not Work in NHS, Raising Concerns Over Access to Care Persistent Offenders Owe Over £700m in Ulez Fines as TfL Cracks Down on Evasion M&S and Morrisons Lead Christmas Supermarket Taste Test New Prostate Cancer Drug Set to Halve Death Risk in England UK Bans Fake Numbers: Scammers Lose Their Trick Reeves rejects £1bn plea for NHS redundancy payouts Northern Lights may illuminate UK skies this week Stroke Patient Mistaken for Drunk, Care Delayed Five-Year-Old Dies After Rare Tonsil Surgery Complication Children to Receive Home Vaccines as England Acts Local Fish Could Boost UK Health and Economy Significantly NHS Violence Crisis: Staff Face Daily Assaults Celebrity Campaign Highlights SMA Screening Failures Pornhub blocks new UK users over age checks dispute AI breast screening cuts later cancer diagnoses by 12%, study finds UK New Car Discounts Near £6,000 as Prices Are Slashed Pneumonia Surge Pushes England Emergency Cases Higher Most Statin Side-Effects Are Not Caused by Drugs, Study Confirms UK MPs Demand Ban on Brazilian Butt Lifts NHS Urges Nine Million People to Get Therapy Half of Britons Avoid GP When Ill, Survey Reveals Growing Concern Father Dies by Suicide Weeks After Wedding in Clitheroe ‘We can’t go back’: mother of six-year-old cancer survivor fears UK visa changes Social Media Giant Trial Reaches Final Jury Decision Charity Watchdog Takes Control of Learning Disability Care Home Councils Pressed to Use Universal Parking App to Cut ‘Unfair’ Fines ‘The Insulation Trap’: Knifeman Discovered Hiding Under Loft Padding After Six-Hour Standoff ‘It’s Heartbreaking’: NHS Training Freeze Leaves Resident Doctors in Limbo The Miracle of Phoenix: ‘Half Dead’ Rescue Dog Defies the Odds in Worcestershire